Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha
- Address
- lock Available on a paid plan
Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha - Military University Hospital Prague
The Military University Hospital Prague serves as a leading clinical research institution conducting diverse therapeutic investigations across multiple medical disciplines. The center demonstrates particular expertise in metabolic disorders, advanced surgical interventions, and specialized treatment modalities for complex conditions.
- Metabolic and hepatic disease research, including non-alcoholic steatohepatitis (NASH) and liver cirrhosis with portal hypertension
- Cardiovascular studies focused on heart failure management and quality of life outcomes
- Neurosurgical interventions with goal-directed fluid management optimization
- Ophthalmologic oncology and retinal disease treatment innovations
The institution is actively involved in phase 2 and phase 3 clinical trials evaluating novel therapeutic approaches, including combination drug therapies for metabolic dysfunction-associated conditions, advanced drug delivery systems for chronic ophthalmic diseases such as neovascular age-related macular degeneration, and innovative treatments for rare conditions like choroidal melanoma. The center's research portfolio reflects a commitment to advancing perioperative care in neurosurgery through non-invasive monitoring technologies and exploring emerging therapeutic targets in cardiovascular and hepatic disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 7 therapeutic areas and 15 of 21 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1F. Hoffmann-La Roche AG2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Janssen Cilag International3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ustredni Vojenska Nemocnice Vojenska Fakultni Nemocnice Praha
lock Showing 1 of 15 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 21 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Milvexian | 3 | Unknown | 2023-08-04 | 2023-11-21 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.